[{"id":"9f7f9253-08cf-4953-b6cf-4724356c6c74","acronym":"","url":"https://clinicaltrials.gov/study/NCT04938115","created_at":"2021-06-24T16:52:55.621Z","updated_at":"2024-07-02T16:34:25.693Z","phase":"","brief_title":"Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia","source_id_and_acronym":"NCT04938115","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • SENL101"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 05/10/2021","start_date":" 05/10/2021","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2024-06-14"},{"id":"f023df74-8e41-4cbc-9129-d952653453b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04916860","created_at":"2021-06-08T15:52:26.751Z","updated_at":"2024-07-02T16:35:51.823Z","phase":"","brief_title":"Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT04916860","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IL6 • IL10 • CD7","pipe":" | ","alterations":" CD7 expression","tags":["IL6 • IL10 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SENL101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-03-31"},{"id":"d4fac740-1c04-4ba5-ad4f-34acb9f47e6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05626400","created_at":"2022-11-23T14:57:15.756Z","updated_at":"2024-07-02T16:35:59.974Z","phase":"","brief_title":"Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL","source_id_and_acronym":"NCT05626400","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD7","pipe":" | ","alterations":" CD7 expression","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SENL101"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/29/2022","start_date":" 08/29/2022","primary_txt":" Primary completion: 10/30/2027","primary_completion_date":" 10/30/2027","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2022-11-24"},{"id":"837c287f-e4ad-4069-8137-fc206c4d0e8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05398614","created_at":"2022-06-01T16:00:15.139Z","updated_at":"2024-07-02T16:36:09.621Z","phase":"Phase 1","brief_title":"SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies","source_id_and_acronym":"NCT05398614","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD8 • CD4 • CD7","pipe":"","alterations":" ","tags":["CD8 • CD4 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SENL101"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-06-01"},{"id":"3cc195a5-8a4c-4bbd-814c-a91da7aaad6a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04928105","created_at":"2021-06-16T18:52:45.866Z","updated_at":"2024-07-02T16:36:09.686Z","phase":"","brief_title":"Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma","source_id_and_acronym":"NCT04928105","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IFNG • IL6 • TNFA • IL10 • CD7","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SENL101"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2022-05-30"},{"id":"91151d5d-4ac8-4997-9821-89c52c8e7599","acronym":"","url":"https://clinicaltrials.gov/study/NCT04572308","created_at":"2021-01-18T21:49:55.166Z","updated_at":"2024-07-02T16:36:28.570Z","phase":"Phase 1","brief_title":"Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells","source_id_and_acronym":"NCT04572308","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IFNG • IL6 • TNFA • IL10 • CD7","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • S1904 • SENL101"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 05/30/2021","primary_completion_date":" 05/30/2021","study_txt":" Completion: 05/30/2021","study_completion_date":" 05/30/2021","last_update_posted":"2021-06-29"}]